HPG7233 / Hepagene Therap - LARVOL DELTA

Hepagene Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for HPG7233 THR Beta Agonist (PRNewswire) - "Hepagene Therapeutics, Inc...announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for its HPG7233, an agonist of Thyroid Hormone Receptor beta (THR-β) for the treatment of patients with non-alcoholic steatohepatitis (NASH) and dyslipidemia."

IND • Non-alcoholic Steatohepatitis